Transparent SRRK Forecast & Balanced News

Trade Smarter With AI models and Balanced News Summaries.


Correlated Stock Forecasts

Assets that tend to move strongly with SRRK

XBI Forecast   SPDR Biotech (0.93)


ME Forecast   23andMe (0.93)


RIVN Forecast   Rivian Automotive (0.92)


PTLO Forecast   Portillos (0.91)


INO Forecast   Inovio Pharmaceuticals (0.9)



Uncorrelated Stock Forecasts

Assets with little price relationship to SRRK

MTB Forecast   M & T (-0.0)


PDD Forecast   Pinduoduo (0.01)


KOLD Forecast   ProShares UltraShort Bloomberg Natural Gas (0.01)


OHI Forecast   Omega Healthcare Investors (-0.01)


JWN Forecast   Nordstrom (-0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against SRRK

SDS Forecast   ProShares UltraShort S&P500 (-0.79)


SH Forecast   ProShares Short S&P500 (-0.79)


VIXM Forecast   ProShares VIX Mid-Term Futures (-0.79)


PSQ Forecast   ProShares Short QQQ (-0.81)


SARK Forecast   Tuttle Capital Short Innovation (-0.83)















      News Sentiment (?): +1.1

Scholar Rock Forecast

Scholar Rock (SRRK)

      

Complement Helium's AI SRRK Forecast with Balanced News and Deepen Your Understanding

HC Wainwright Weighs in on Scholar Rock Holding Co.'s FY2022 Earnings (NASDAQ:SRRK) - MarketBeat

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Rating) - HC Wainwright lifted their FY2022 earnings per share estimates for shares of Scholar Rock in a research report issued to clients and investors on Tuesday, November 15th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($2.35) per share for the year, up from their prior estimate of ($3.01). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Scholar Rock's Q4 2022 earnings at ($0.53) EPS, Q1 2023 earnings at ($0.53) EPS, Q2 2023 earnings at ($0.53) EPS, ...
marketbeat.com     Nov 19, 2022

STAT+: This billionaire has quietly driven Boston’s biotech industry for decades

STAT+: This billionaire has quietly driven Boston’s biotech industry for decades

tech

Springer, a 74-year-old professor at Harvard Medical School and a research lab chief at Boston Children’s Hospital, is a heads-down scientist and entrepreneur with some notable quirks. He once commissioned a modern dance piece to explain the behavior of a kind of protein he studies called an integrin. He has shipped many tons of nature-sculpted “scholar rocks,” or gongshi, from China to his home in Newton, where they are displayed in his back yard. He says that during his freshman year at Yale in the mid-1960s, he rebelled against the requirement to wear a tie by putting one on over a t-shirt.
STAT     Jul 29, 2022